Association of Marijuana Use with Changes in Cognitive Processing Speed and Flexibility for 17 Years in HIV-Seropositive and HIV-Seronegative Men.
HIV
Marijuana
cognition
longitudinal
Journal
Substance use & misuse
ISSN: 1532-2491
Titre abrégé: Subst Use Misuse
Pays: England
ID NLM: 9602153
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
1
2
2019
medline:
21
1
2020
entrez:
1
2
2019
Statut:
ppublish
Résumé
The long-term effects of marijuana on cognition, particularly in the context of HIV is not clear, as extant research shows mixed findings. To determine associations between current and cumulative exposure to marijuana and changes in cognitive processing speed and flexibility in 788 HIV-seropositive (HIV+) and 1,132 HIV-seronegative (HIV-) men followed for up to 17 years in the Multicenter AIDS Cohort Study. Among HIV+ men only, current daily marijuana use compared to none-use, was significantly associated with a greater annual percentage decline in cognitive processing speed assessed with the Trail Making Test A (TMTA) (β=-0.41, 95% confidence interval (CI): -0.88, -0.03, p=0.03)] and Symbol Digit Modalities Test (SDMT) (β= -0.14, 95% CI: -0.28, -0.01, p=0.04). Further, monthly marijuana use was associated with greater annual percentage decline in cognitive flexibility assessed with the Trail Making Test B (TMTB) (β= -0.70, 95% CI: -1.34, -0.05; p=0.03] and cognitive processing speed (SDMT) (β= -0.21, 95% CI: -0.40, -0.01, p=0.03). Among the HIV- men only, each 5-marijuana use-years (equivalent to 5-years of daily marijuana use) was significantly associated with a 0.17 annual percentage decline in cognitive processing speed only (TMTA) (β= -0.18, 95% CI: -0.36, -0.01; p=0.04). Our findings suggest that marijuana use, particularly current use, may be associated with worse cognitive processing speed, but the magnitude of the estimates was not clinically meaningful.
Sections du résumé
BACKGROUND
The long-term effects of marijuana on cognition, particularly in the context of HIV is not clear, as extant research shows mixed findings.
OBJECTIVE
To determine associations between current and cumulative exposure to marijuana and changes in cognitive processing speed and flexibility in 788 HIV-seropositive (HIV+) and 1,132 HIV-seronegative (HIV-) men followed for up to 17 years in the Multicenter AIDS Cohort Study.
RESULTS
Among HIV+ men only, current daily marijuana use compared to none-use, was significantly associated with a greater annual percentage decline in cognitive processing speed assessed with the Trail Making Test A (TMTA) (β=-0.41, 95% confidence interval (CI): -0.88, -0.03, p=0.03)] and Symbol Digit Modalities Test (SDMT) (β= -0.14, 95% CI: -0.28, -0.01, p=0.04). Further, monthly marijuana use was associated with greater annual percentage decline in cognitive flexibility assessed with the Trail Making Test B (TMTB) (β= -0.70, 95% CI: -1.34, -0.05; p=0.03] and cognitive processing speed (SDMT) (β= -0.21, 95% CI: -0.40, -0.01, p=0.03). Among the HIV- men only, each 5-marijuana use-years (equivalent to 5-years of daily marijuana use) was significantly associated with a 0.17 annual percentage decline in cognitive processing speed only (TMTA) (β= -0.18, 95% CI: -0.36, -0.01; p=0.04).
CONCLUSIONS
Our findings suggest that marijuana use, particularly current use, may be associated with worse cognitive processing speed, but the magnitude of the estimates was not clinically meaningful.
Identifiants
pubmed: 30700235
doi: 10.1080/10826084.2018.1495736
pmc: PMC6443451
mid: NIHMS1514762
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-537Subventions
Organisme : NIAID NIH HHS
ID : U01 AI035042
Pays : United States
Organisme : NIAAA NIH HHS
ID : U24 AA022002
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146201
Pays : United States
Organisme : NIMH NIH HHS
ID : T32 MH080634
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH058107
Pays : United States
Organisme : NIDA NIH HHS
ID : F31 DA039810
Pays : United States
Références
Neurology. 2002 Dec 24;59(12):1944-50
pubmed: 12499488
J Neurovirol. 2011 Feb;17(1):3-16
pubmed: 21174240
Int J STD AIDS. 2012 Aug;23(8):576-80
pubmed: 22930295
Neuropsychol Rev. 2013 Jun;23(2):117-37
pubmed: 23129391
CMAJ. 2002 Apr 2;166(7):887-91
pubmed: 11949984
Front Psychol. 2012 Apr 17;3:111
pubmed: 22529829
J Addict Med. 2011 Mar;5(1):1-8
pubmed: 21321675
Am J Psychiatry. 2016 Jun 1;173(6):588-99
pubmed: 26940807
J Subst Abuse Treat. 2017 Nov;82:102-106
pubmed: 29021107
Am J Epidemiol. 1995 Aug 1;142(3):323-30
pubmed: 7631636
Annu Rev Psychol. 2013;64:21-47
pubmed: 22804774
J Sex Med. 2012 Apr;9(4):1106-13
pubmed: 22321450
Am J Drug Alcohol Abuse. 2017 Jan;43(1):103-110
pubmed: 27398989
Subst Abus. 2018 Jan 2;39(1):116-123
pubmed: 29058572
JAMA Intern Med. 2016 Mar;176(3):352-61
pubmed: 26831916
Clin Nurs Res. 2009 May;18(2):172-93
pubmed: 19377043
Pharmacol Ther. 1997;74(2):129-80
pubmed: 9336020
Pharmacotherapy. 2004 Jan;24(1):69-78
pubmed: 14740789
J Mol Psychiatry. 2014 Mar 04;2(1):2
pubmed: 25945248
J Clin Psychiatry. 2012 Mar;73(3):384-91
pubmed: 22053858
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
pubmed: 1361652
Psychopharmacology (Berl). 2006 Nov;188(4):425-44
pubmed: 17019571
Front Psychiatry. 2013 Jul 01;4:53
pubmed: 23847550
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
pubmed: 2308954
JAMA Psychiatry. 2016 Apr;73(4):388-95
pubmed: 26886046
Clin Immunol Immunopathol. 1990 May;55(2):173-86
pubmed: 1969782
Exp Clin Psychopharmacol. 2012 Oct;20(5):420-429
pubmed: 22731735
Neuroscience. 1997 Mar;77(2):299-318
pubmed: 9472392
Epidemiology. 2012 Jan;23(1):119-28
pubmed: 21989136
AIDS Patient Care STDS. 2004 Apr;18(4):215-28
pubmed: 15142352
Clin Pharmacokinet. 2003;42(4):327-60
pubmed: 12648025
Br J Psychiatry. 2010 Oct;197(4):285-90
pubmed: 20884951
Drug Alcohol Depend. 2016 Feb 1;159:72-9
pubmed: 26686277
Am J Drug Alcohol Abuse. 2017 Sep;43(5):556-566
pubmed: 27808576
J Neuropsychiatry Clin Neurosci. 2004 Summer;16(3):330-5
pubmed: 15377740
J Psychopharmacol. 2013 Jan;27(1):19-27
pubmed: 23042808
Neuroscience. 1994 Dec;63(3):637-52
pubmed: 7898667
Annu Rev Med. 2016;67:453-66
pubmed: 26515984
Front Pharmacol. 2016 Oct 13;7:355
pubmed: 27790138
CMAJ. 2010 Oct 5;182(14):E694-701
pubmed: 20805210
Lancet Infect Dis. 2013 Nov;13(11):976-86
pubmed: 24156898
J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):618-26
pubmed: 23011399
Psychosomatics. 2015 Sep-Oct;56(5):470-8
pubmed: 25656425
Drug Alcohol Depend. 2016 Dec 01;169:134-140
pubmed: 27810656
J Neurovirol. 2004 Dec;10(6):350-7
pubmed: 15765806
AIDS Care. 2016;28(5):628-32
pubmed: 26694807
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64
pubmed: 22927402
JAMA. 2002 Mar 6;287(9):1123-31
pubmed: 11879109
Curr Opin Neurol. 2011 Jun;24(3):275-83
pubmed: 21467932
Drug Alcohol Depend. 2017 Jan 01;170:120-127
pubmed: 27889592
Am J Epidemiol. 1987 Aug;126(2):310-8
pubmed: 3300281
HIV AIDS (Auckl). 2015 Jan 29;7:35-47
pubmed: 25678819
J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):82-92
pubmed: 11176272
J Neuroimmune Pharmacol. 2006 Mar;1(1):65-76
pubmed: 18040792
J Clin Exp Neuropsychol. 2011 Aug;33(7):735-52
pubmed: 21480022
J Int Neuropsychol Soc. 2003 Jul;9(5):679-89
pubmed: 12901774
Am J Public Health. 2013 Aug;103(8):1457-67
pubmed: 23763417
Neuropsychol Rev. 2007 Sep;17(3):347-61
pubmed: 17680367
Addiction. 2011 Dec;106(12):2195-203
pubmed: 21749524
Handb Exp Pharmacol. 2005;(168):299-325
pubmed: 16596779
PLoS One. 2013;8(3):e58812
pubmed: 23554932
Curr Addict Rep. 2014 Jun 1;1(2):144-156
pubmed: 25013751
AIDS Behav. 2016 Mar;20(3):622-32
pubmed: 26093780
AIDS Behav. 2018 May;22(5):1596-1605
pubmed: 28884250
JAMA Psychiatry. 2015 Dec;72(12):1235-42
pubmed: 26502112